| Literature DB >> 34322877 |
Xiuxiu Yang1,2,3, Yaxin Guo4,5,3, Chen Chen3,6, Bo Shao1,3, Luyang Zhao4,5,3, Quanbo Zhou1, Jinbo Liu1, Guixian Wang1, Weitang Yuan1, Zhenqiang Sun1,3.
Abstract
In recent years, an increasing number of studies have reported that intestinal microbiota have an important effect on tumour immunity by affecting the tumour microenvironment (TME). The intestinal microbiota are closely associated with various immune cells, such as T lymphocytes, Natural killer cells(NK cells) and macrophages. Some bacteria, such as Akkermansia muciniphila (A. muciniphila) and Lactobacillus reuteri (L. reuteri), have been shown to improve the effect of tumour immunity. Furthermore, microbial imbalance, such as the increased abundance of Fusobacterium nucleatum (F. nucleatum) and Helicobacter hepaticus (H. hepaticus), generally causes tumour formation and progression. In addition, some microbiota also play important roles in tumour immunotherapy, especially PD-L1-related therapies. Therefore, what is the relationship between these processes and how do they affect each other? In this review, we summarize the interactions and corresponding mechanisms among the intestinal microbiota, immune system and TME to facilitate the research and development of new targeted drugs and provide new approaches to tumour therapy. This article is protected by copyright. All rights reserved.Entities:
Keywords: Immune; Intestinal microbiota; TME; Tumour therapy
Year: 2021 PMID: 34322877 DOI: 10.1111/imm.13397
Source DB: PubMed Journal: Immunology ISSN: 0019-2805 Impact factor: 7.397